The Wolverine stack is the most talked-about recovery combination in the peptide world: BPC-157 and TB-500 run together. The logic behind pairing them is real, the two work through genuinely different mechanisms, but the stack also inherits the same honest limitation both compounds carry on their own, which is a deep animal-research record and very little human proof. Here is the full breakdown of what the stack is, why the two are combined, how each is dosed in research-reference terms, and where the evidence actually stands.
What is the Wolverine stack?
The Wolverine stack is a research peptide combination of BPC-157 and TB-500 (Thymosin Beta-4). The two are paired because they are considered mechanistically complementary in preclinical tissue-repair models: BPC-157 provides local growth-factor upregulation and angiogenesis, while TB-500 provides systemic, actin-mediated cell migration. They are sometimes sold as a pre-mixed blend vial (for example, a 10 mg BPC-157 plus 10 mg TB-500 combination) and sometimes run as two separate compounds co-administered. They are not interchangeable, and published co-administration research has not established a single standardized ratio between them.
How it works
The reason the pairing makes sense is that the two peptides cover different parts of the same repair process.
BPC-157 works locally, at the site of injury. It drives tissue repair through growth-factor upregulation, including increased VEGF and EGF expression, fibroblast proliferation, angiogenesis in connective tissue, and satellite-cell activation in muscle models. It creates the local signaling environment that repair requires, concentrated where it is administered.
TB-500 works systemically, through a different primary mechanism: actin regulation. Thymosin Beta-4 is the main intracellular actin-sequestering peptide in mammalian cells, and it regulates the ratio of G-actin to F-actin, which governs how cells migrate, extend, and reorganize during tissue repair. In practical terms, TB-500 helps repair cells move toward and through the injury, and it supports the growth of new blood supply across muscle, tendon, and other tissue.
So the stack pairs a local repair signal (BPC-157) with a systemic cell-migration and circulation driver (TB-500). One sets up the repair environment at the injury; the other helps the body mobilize and move the cells that do the rebuilding. That division of labor is the entire rationale for running them together rather than either alone.
The evidence
Both compounds share the same honest evidence profile, and so does the stack. A current review of the two describes them as exerting broad effects on wound healing, angiogenesis, tissue regeneration, and inflammatory modulation, but that conclusion rests on preclinical investigations and only limited clinical data. BPC-157 has no published Phase 2 or Phase 3 human trials; the only human BPC-157 data is small pilot safety work. TB-500's documented doses come almost entirely from animal models, and its standardized human therapeutic dose has not been established. There is no controlled human trial of the combination itself.
The fair read: the mechanisms are well-described in animals and complement each other on paper, but the human efficacy evidence for the stack is essentially absent. It is a research combination with a strong preclinical rationale and an empty human-trial record.
Dosing (research reference)
Because the stack is two compounds, the reference dosing is best understood per peptide.
BPC-157: research-reference protocols most commonly cite 250 to 500 mcg daily, sometimes split into two doses, often run as a 4 to 6 week cycle for simpler tissue and longer for slower-remodeling models.
TB-500: reference protocols commonly cite 2 to 5 mg weekly, used systemically, sometimes split across two injections per week given its long-acting nature. A frequently referenced muscle-injury regimen pairs BPC-157 at 250 to 500 mcg with thymosin beta-4 at 2 to 5 mg twice weekly, by subcutaneous injection.
For the pre-mixed blend format, a common reference is a 10 mg BPC-157 plus 10 mg TB-500 vial reconstituted with 2 mL of bacteriostatic water, which gives 5,000 mcg/mL of each peptide, meaning every unit drawn contains equal parts of both. Because the blend locks the two peptides into a fixed ratio, running them as separate vials is what allows the doses to be adjusted independently, which is the main practical reason some research-reference protocols favor separate administration over the blend.
Side effects and regulatory status
In the limited research available, both peptides are generally described as well-tolerated, with mild injection-site reactions the most commonly noted issue. The honest caveats are significant: long-term human safety is not established for either compound, the FDA has flagged concerns with compounded BPC-157 (including immunogenicity and impurity risks), and both BPC-157 and TB-500 are banned in sport. For a tested athlete, the stack is off the table entirely.
Where it fits
The Wolverine stack is the local-plus-systemic recovery pairing, and the rationale behind it is sound: BPC-157 sets up repair at the injury, TB-500 mobilizes the systemic side. Its appeal is strongest for bigger or stubborn injuries where a single local compound seems to stall. But the stack is still a research combination built on animal data and mechanism, not human outcomes, and it carries unresolved safety and regulatory questions. Treated as a mechanism-backed research tool with thin human proof, layered on top of real rehab rather than replacing it, it is framed honestly. Sold as a proven healing protocol, it is overstated.